FDA has approved Enhertu (fam-trastuzumab-deruxtecan-nxki), the first approved therapy targeted to patients with unresectable or metastatic HER2-low breast cancer subtype, a newly defined subset of HER2-negative breast cancer.
Source: Drug Industry Daily